Regulating TMEM219 by blocking the interaction between the protein and its ligand, IGFBP3, restored the self-renewal capabilities in vitro in patient-derived organoids (PDOs). These results were ...

The findings support Enthera's clinical development of Ebrasodebart, a monoclonal antibody that targets the IGFBP3/TMEM219 pathway for the treatment of IBD, including UC and Crohn's disease.

Previous studies conducted by the same group of researchers had highlighted the importance of the IGFBP3 / TMEM219 signaling in the context of diabetes, particularly on insulin-producing beta cells.

Previous studies conducted by the same group of researchers had highlighted the importance of the IGFBP3 / TMEM219 signaling in the context of diabetes, particularly on insulin-producing beta cells.

Researchers Identify Key Mechanism in Human Lung Development Oct. 31, 2024 — Researchers have shown that the IGFBP3 protein plays a relevant role in human lung development. The results of the ...

Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing a first-in-class antibody therapeutic targeting the Insulin Growth Factor Binding Protein 3 (IGFBP3)/TMEM219 ...

The findings support Enthera’s clinical development of Ebrasodebart, a monoclonal antibody that targets the IGFBP3/TMEM219 pathway for the treatment of IBD, including UC and Crohn’s disease. The ...

Previous studies conducted by the same group of researchers had highlighted the importance of the IGFBP3 / TMEM219 signaling in the context of diabetes, particularly on insulin-producing beta cells.

PANC-1 with IGFBP3-knockdown generated via siRNA (Santa cruz biotechnology, sc-39587) were cultured in DMEM supplemented with 10% fetal bovine serum under standard conditions (37°C, 5% CO2). When ...

These phenomena point to an enhanced insulin-like activity caused by the action of IGF-2, which competes for insulin and IGF-1 receptors, and inhibits the secretion of growth hormone (GH), inhibiting ...